ITGAL and psoriatic arthritis: Indeed, the anti-CD11a monoclonal antibody (mAb) efalizumab was used to treat autoimmune diseases, including psoriasis and psoriatic arthritis, and was tested in rheumatoid arthritis (Table S2) before being withdrawn for safety issues.